Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/88189
Title: | ADAM9 mediates triple-negative breast cancer progression via AKT/NF-kappa B pathway | Authors: | Zhou, R Cho, WCS Ma, V Cheuk, W So, YK Wong, SCC Zhang, MR Li, C Sun, YJ Zhang, H Chan, LWC Tian, M |
Issue Date: | Jun-2020 | Source: | Frontiers in medicine, June 2020, v. 7, 214, p. 1-13 | Abstract: | Upregulation of a disintegrin and metalloprotease 9 (ADAM9) is correlated with progression of cancers, such as prostate, bladder, and pancreatic cancers. However, its role in triple-negative breast cancer (TNBC) is still unclear. Our study aimed to investigate whether ADAM9 is upregulated and promoted the aggressiveness in TNBC. Breast cancer cell lines and patient specimens were used to evaluate the ADAM9 expression by western blotting and immunohistochemistry staining, respectively. Compared with the non-TNBC, ADAM9 expression was significantly increased in TNBC cells and TNBC patient specimens. Based on the data acquired from public databases, the correlation between ADAM9 expression and breast cancer patient survival was analyzed by Kaplan-Meier method. It was shown that ADAM9 overexpression was significantly correlated with poorer survival in patients with TNBC. Furthermore, ADAM9 in TNBC cells was knocked down by small interference RNA and then studied by the MTT/colony formation assay, wound healing assay and transwell invasion assay on the cell proliferation, migration, and invasion, respectively. We found that inhibiting ADAM9 expression suppressed TNBC cell proliferation, migration, and invasion by lowering the activation of AKT/NF-kappa B pathway. Our results demonstrated that ADAM9 is an important molecule in mediating TNBC aggressiveness and may be a potential useful therapeutic target in TNBC treatment. | Keywords: | A disintegrin and metalloprotease 9 (ADAM9) AKT NF-kappa B Triple-negative breast cancer (TNBC) Tumor progression |
Publisher: | Frontiers Research Foundation | Journal: | Frontiers in medicine | EISSN: | 2296-858X | DOI: | 10.3389/fmed.2020.00214 | Rights: | © 2020 Zhou, Cho, Ma, Cheuk, So, Wong, Zhang, Li, Sun, Zhang, Chan and Tian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. The following publication Zhou, R., Cho, W. C. S., Ma, V., Cheuk, W., So, Y. K., Wong, S. C. C., . . . Tian, M. (2020). ADAM9 mediates triple-negative breast cancer progression via AKT/NF-kappa B pathway. Frontiers in Medicine, 7, 1-13 is available at https://dx.doi.org/10.3389/fmed.2020.00214 |
Appears in Collections: | Journal/Magazine Article |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Zhou_ADAM9_Mediates_Triple-Negative.pdf | 2.19 MB | Adobe PDF | View/Open |
Page views
85
Last Week
0
0
Last month
Citations as of Sep 22, 2024
Downloads
38
Citations as of Sep 22, 2024
SCOPUSTM
Citations
15
Citations as of Sep 26, 2024
WEB OF SCIENCETM
Citations
15
Citations as of Sep 26, 2024
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.